GlassScriptPhysician profile
Caleb C Huffman
NPI 1265108393
$4,793.08
in general payments reported to CMS, 2019-2025
28 companies · $1,771 in 2025
The $1,771 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $941 · 2024: $2,081 · 2025: $1,771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,648 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,648.09 |
| Education | $144.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $978.99 | 2023-2025 | Otezla, Enbrel, Krystexxa |
| Janssen Biotech, INC. | $833.11 | 2023-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $355.45 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.51 | 2023-2025 | Ofev, Cyltezo |
| Astrazeneca Pharmaceuticals LP | $284.40 | 2023-2025 | Saphnelo |
| Ucb, INC. | $253.36 | 2023-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $235.00 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $231.45 | 2023-2025 | |
| Lilly USA, LLC | $219.91 | 2023-2025 | Taltz |
| Radius Health, INC. | $138.04 | 2023-2025 | Tymlos |
| Glaxosmithkline, LLC. | $111.15 | 2023-2025 | Benlysta |
| Ani Pharmaceuticals, INC. | $103.23 | 2024-2025 | Purified Cortrophin Gel |
| Janssen Scientific Affairs, LLC | $102.97 | 2025 | Tremfya |
| Aurinia Pharma U.S., INC. | $95.85 | 2023-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $75.05 | 2023-2025 | Strensiq |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $70.46 | 2023-2025 | Hyrimoz |
| Sobi, INC | $61.51 | 2023-2025 | |
| Almatica Pharma LLC | $60.72 | 2024-2025 | Teriparatide |
| Organon LLC | $57.33 | 2023-2025 | Hadlima, Renflexis |
| Scilex Pharmaceuticals INC. | $47.73 | 2024 | |
| Genentech USA, INC. | $38.28 | 2025 | Actemra |
| Fresenius Kabi USA, LLC | $31.85 | 2025 | |
| Mallinckrodt Hospital Products INC. | $27.43 | 2025 | Acthar |
| Ultragenyx Pharmaceutical INC. | $22.70 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $21.94 | 2024 | Arcalyst |
| Genzyme Corporation | $17.16 | 2023 | |
| Horizon Therapeutics Plc | $16.01 | 2023 | Krystexxa |
| Actelion Pharmaceuticals US, INC. | $14.49 | 2024 | Opsumit, Uptravi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Huffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.